about
Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis.PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis.Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.Relationship between increased body iron stores, oxidative stress and insulin resistance in healthy men.Avidity of antineurocytoskeletal antibodies in Alzheimer's disease patients.Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study.Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies.Oxidative stress and inflammation in pregnancyAntiphospholipid Antibodies in Patients with Lupus NephritisCerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosisElevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosisAntibodies against light neurofilaments in multiple sclerosis patientsIron stores are associated with asymptomatic atherosclerosis in healthy men of primary preventionAvidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serumPatients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilamentCerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis
P50
Q35580278-CA8DABBE-7F7A-4E01-B606-FEA1F81F53D1Q44249482-6C418C90-1593-4C02-9003-575876B0FFB5Q44403860-BBB36920-9BE4-41A7-9DAE-90012A9B23B9Q44683765-8084BFC4-6E78-4ECF-B5E6-82BBC81A2127Q45916467-994331F3-C9BF-4330-ADF7-7C9884B8E6BAQ47737636-21CB11AE-C9DD-4EC6-ACAD-7ED56F3328BEQ48541262-2788EF26-AE28-4BC0-BEC9-FEE35DF192DCQ53546485-F9FA1D46-68EC-44B3-BEA2-E05E1C59A4F2Q57825373-B248E3DE-EA5E-494E-9888-3D6D6057DEDFQ57825441-3D740F75-BFB6-4D14-A153-7EDAE205DA9AQ79761200-A98F2DAA-2609-48A0-A330-0CE377E887D5Q80347950-E8679D90-968D-40B2-B7B5-011E926C2683Q80697259-D57C4153-9EDA-4548-B956-3EFF888BAF72Q83330614-3FEA3374-EF97-4819-A4B2-E153BF6D3700Q84080331-6717A97E-A88F-497E-B718-37CF740FC34AQ84935000-93489D08-BE5E-456D-9325-9AF9CC946E9BQ84997443-102C5C3B-E3C5-4EF5-8D88-17A4D3E0B1B0
P50
description
biochemička
@cs
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lenka Fialová
@ast
Lenka Fialová
@cs
Lenka Fialová
@en
Lenka Fialová
@es
Lenka Fialová
@nl
Lenka Fialová
@sl
type
label
Lenka Fialová
@ast
Lenka Fialová
@cs
Lenka Fialová
@en
Lenka Fialová
@es
Lenka Fialová
@nl
Lenka Fialová
@sl
prefLabel
Lenka Fialová
@ast
Lenka Fialová
@cs
Lenka Fialová
@en
Lenka Fialová
@es
Lenka Fialová
@nl
Lenka Fialová
@sl
P214
P1153
7004318473
P19
P21
P214
P31
P496
0000-0001-8137-7771
P569
1957-03-01T00:00:00Z